{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:20:47Z","timestamp":1793740847920,"version":"4.6.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunosuppressive therapy using horse antithymocyte globulin (ATG; h-ATG) combined with cyclosporine (CsA) and eltrombopag is the standard care for aplastic anemia (AA) in patients without a suitable matched donor. However, in many countries, h-ATG use has been discontinued, leaving rabbit ATG (r-ATG), which has a lower response rates and poorer survival, as the only alternative. In previous studies, alemtuzumab (ALZ), a humanized monoclonal antibody targeting CD52, combined with CsA, resulted in an adequate overall response rate (ORR) in patients with AA. This study describes a multicenter, international retrospective analysis of ALZ for treating AA.We analyzed a series of patients who received subcutaneous ALZ for AA in 4 centers in Brazil and the United Kingdom from March 2009 to January 2024. We analyzed 64 ALZ treatments in 61 adult patients with AA, 76% with severe AA (SAA) or very SAA. The ORR was 59.4% at 12\u00a0months (complete, 21.9%; partial, 37.5%). Cumulative incidence (CI) of response was 54.7% at 6\u00a0months and 59.4% at 12\u00a0months. Younger patients (age &amp;lt;65 years) had higher CI of response (67% vs 31%; P\u00a0=\u00a0.03), as did patients treated with a total dose of 103\u00a0mg (70% vs 38%; P\u00a0=\u00a0.02). Overall survival was 86% at 1 year, 78% at 2 years, and 70% at 4 years, significantly higher in responders (90% vs 44%; P\u00a0&amp;lt; .0001). Adverse events were of low grade, and infectious events were infrequent. Subcutaneous ALZ is a feasible, effective, and safe alternative to r-ATG for patients with AA requiring immunosuppressive treatment when h-ATG access is limited.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014159","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T20:08:40Z","timestamp":1734552520000},"page":"906-912","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5615-9614","authenticated-orcid":false,"given":"Ana Rita","family":"da Fonseca","sequence":"first","affiliation":[{"name":"1Department of Clinical and Experimental Hematology, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"2Hospital S\u00edrio Liban\u00eas, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-8124","authenticated-orcid":false,"given":"Caio Cesar","family":"Justino","sequence":"additional","affiliation":[{"name":"1Department of Clinical and Experimental Hematology, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3598-2572","authenticated-orcid":false,"given":"Vinicius","family":"Campos de Molla","sequence":"additional","affiliation":[{"name":"1Department of Clinical and Experimental Hematology, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"3Division of Hematology, Hospital Nove de Julho, Rede DASA, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5675-0893","authenticated-orcid":false,"given":"Patricia Eiko","family":"Yamakawa","sequence":"additional","affiliation":[{"name":"1Department of Clinical and Experimental Hematology, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iara Baldim","family":"Rabelo","sequence":"additional","affiliation":[{"name":"1Department of Clinical and Experimental Hematology, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Arnold","sequence":"additional","affiliation":[{"name":"4Department of Haematology, St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kelly","sequence":"additional","affiliation":[{"name":"4Department of Haematology, St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag","family":"Griffin","sequence":"additional","affiliation":[{"name":"4Department of Haematology, St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"4Department of Haematology, St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Hill","sequence":"additional","affiliation":[{"name":"5Alexion Pharmaceuticals Inc, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-0579","authenticated-orcid":false,"given":"Elvira","family":"Velloso","sequence":"additional","affiliation":[{"name":"6Hematology Unit, Hospital das Cl\u00ednicas, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"7Department of Clinical Medicine and Surgery, University of Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales","family":"Dalessandro","sequence":"additional","affiliation":[{"name":"6Hematology Unit, Hospital das Cl\u00ednicas, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"7Department of Clinical Medicine and Surgery, University of Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-5109","authenticated-orcid":false,"given":"Antonio M.","family":"Risitano","sequence":"additional","affiliation":[{"name":"8Severe Aplastic Anemia Working Party, European Group for Blood and Marrow Transplantation, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"8Severe Aplastic Anemia Working Party, European Group for Blood and Marrow Transplantation, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin","family":"Kulasekararaj","sequence":"additional","affiliation":[{"name":"9Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6395-6849","authenticated-orcid":false,"given":"Celso","family":"Arrais-Rodrigues","sequence":"additional","affiliation":[{"name":"1Department of Clinical and Experimental Hematology, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"3Division of Hematology, Hospital Nove de Julho, Rede DASA, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"17","key":"2025032418272233500_bib1","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic anemia","volume":"379","author":"Young","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025032418272233500_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.hoc.2018.03.001","article-title":"The pathophysiology of acquired aplastic anemia: current concepts revisited","volume":"32","author":"Schoettler","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2025032418272233500_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032418272233500_bib4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjh.17403","article-title":"Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries","volume":"194","author":"Scheinberg","year":"2021","journal-title":"Br J Haematol"},{"issue":"15","key":"2025032418272233500_bib5","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/bloodadvances.2018021162","article-title":"Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment","volume":"2","author":"Georges","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2025032418272233500_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/bmt.2012.223","article-title":"Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor","volume":"48","author":"Aljurf","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2025032418272233500_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.25081","article-title":"First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: outcome of 955 patients treated 2001-2012","volume":"93","author":"Bacigalupo","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2025032418272233500_bib8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3324\/haematol.2008.002170","article-title":"Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis","volume":"94","author":"Gurion","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2025032418272233500_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2141.2006.06085.x","article-title":"Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil","volume":"133","author":"Scheinberg","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"2025032418272233500_bib10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3324\/haematol.13829","article-title":"Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study","volume":"94","author":"Scheinberg","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"2025032418272233500_bib11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2025032418272233500_bib12","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1182\/blood-2012-02-407684","article-title":"Prospective study of rabbit ATG and CyA for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party","volume":"119","author":"Marsh","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2025032418272233500_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2018.1.450","article-title":"Activity of eltrombopag in severe aplastic anemia","volume":"2018","author":"Scheinberg","year":"2018","journal-title":"Hematology"},{"issue":"1","key":"2025032418272233500_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2025032418272233500_bib15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025032418272233500_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/hem.V19.3.2022312","article-title":"Eltrombopag in frontline therapy for severe aplastic anemia: a RACE against time","volume":"19","author":"Anderson","year":"2022","journal-title":"Hematologist"},{"issue":"12","key":"2025032418272233500_bib17","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2025032418272233500_bib18","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00277-018-3416-4","article-title":"Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study","volume":"97","author":"Cl\u00e9","year":"2018","journal-title":"Ann Hematol"},{"issue":"5","key":"2025032418272233500_bib19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1365-2141.2009.08027.x","article-title":"Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA","volume":"148","author":"Risitano","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2025032418272233500_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1634\/theoncologist.2007-0218","article-title":"FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia","volume":"13","author":"Demko","year":"2008","journal-title":"Oncologist"},{"issue":"9856","key":"2025032418272233500_bib21","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"2025032418272233500_bib22","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.tp.0000219235.97036.9c","article-title":"Alemtuzumab (Campath-1H): a systematic review in organ transplantation","volume":"81","author":"Morris","year":"2006","journal-title":"Transplantation"},{"issue":"1","key":"2025032418272233500_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbmt.2007.08.052","article-title":"Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease","volume":"14","author":"G\u00f3mez-Almaguer","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2025032418272233500_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","article-title":"Pharmacokinetics of alemtuzumab used for in\u00a0vivo and in\u00a0vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications","volume":"102","author":"Morris","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2025032418272233500_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood-2011-05-352328","article-title":"Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia","volume":"119","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2025032418272233500_bib26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/ajh.26924","article-title":"Alemtuzumab in relapsed immune severe aplastic anemia: long-term results of a phase II study","volume":"98","author":"Aggarwal","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"2025032418272233500_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2141.1988.tb02460.x","article-title":"Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA Working Party","volume":"70","author":"Bacigalupo","year":"1988","journal-title":"Br J Haematol"},{"issue":"3","key":"2025032418272233500_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V45.3.355.355","article-title":"Selection of patients for bone marrow transplantation in severe aplastic anemia","volume":"45","author":"Camitta","year":"1975","journal-title":"Blood"},{"issue":"1","key":"2025032418272233500_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.14907","article-title":"Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions","volume":"183","author":"Thota","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2025032418272233500_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00277-009-0816-5","article-title":"Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia","volume":"89","author":"G\u00f3mez-Almaguer","year":"2010","journal-title":"Ann Hematol"},{"issue":"2","key":"2025032418272233500_bib31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.leukres.2008.08.004","article-title":"A\u00a0pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome","volume":"33","author":"Kim","year":"2009","journal-title":"Leuk Res"},{"issue":"4","key":"2025032418272233500_bib32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1365-2141.2001.03039.x","article-title":"The effect of treatment with Campath-1H in patients with autoimmune cytopenias","volume":"114","author":"Willis","year":"2001","journal-title":"Br J Haematol"},{"issue":"2","key":"2025032418272233500_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/bmt.2012.245","article-title":"Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab)","volume":"48","author":"Risitano","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2025032418272233500_bib34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41409-019-0773-0","article-title":"Haploidentical transplantation and post- transplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party","volume":"55","author":"Prata","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2025032418272233500_bib35","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.bbmt.2012.07.004","article-title":"Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia","volume":"18","author":"Atta","year":"2012","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/906\/2356318\/blooda_adv-2024-014159-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/906\/2356318\/blooda_adv-2024-014159-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:05:14Z","timestamp":1742846714000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/906\/534655\/Outpatient-subcutaneous-alemtuzumab-is-feasible"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014159","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]}}}